Claims for Patent: 5,786,347

Summary for Patent: 5,786,347

Title:	Vitamin D amine and amide derivatives
Abstract:	The invention relates to vitamin D amine and amide derivatives of general formula ##STR1## where R represents a hydrogen atom, an aliphatic, cycloaliphatic or araliphatic group, or an acyl group comprising an aliphatic, cycloaliphatic, arylaliphatic or aryl group linked to the nitrogen atom by way of a carbonyl group; R.sup.1 and R.sup.2 are each selected from lower alkyl and cycloalkyl groups or together with the carbon atom to which they are attached form a lower cycloalkyl group; R.sup.3 represents a methyl group having .alpha.- or .beta.-configuration; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and A.dbd. represents a cyclohexylidene moiety characteristic of the A-ring of a 1 .alpha.-hydroxylated vitamin D or analogue thereof. Active compounds of the invention exhibit cell modulating activity and in certain cases may also have an effect on calcium metabolism. The compounds of the invention may be prepared by isomerizing a 5,6-trans isomer of formula (I) to a corresponding 5,6-cis isomer; by hydroxylating a 1-unsubstituted-5,6-trans analogue of a compound of formula (I) to prepare a 5,6-trans isomer of formula (I); by reacting a compound containing a precursor for the desired 17-position side chain in one or more stages and with one or more reactants serving to form the desired side chain; or by reacting a compound of formula (I) to modify the substitution pattern about the A.dbd. group.
Inventor(s):	Hesse; Robert Henry (Winchester, MA), Setty; Sundara Katugam Srinivasaetty (Cambridge, MA), Ramgopal; Malathi (Andover, MA)
Assignee:	Research Institute for Medicine and Chemistry, Inc. (Cambridge, MA)
Application Number:	08/652,597
Patent Claims:	1. A compound of general formula (I) ##STR17## where R represents a hydrogen atom, an aliphatic, cycloaliphatic or araliphatic group, or an acyl group comprising an aliphatic, cycloaliphatic, arylaliphatic or aryl group linked to the nitrogen atom by way of a carbonyl group; R.sup.1 and R.sup.2 are each selected from lower alkyl and cycloalkyl groups or together with the carbon atom to which they are attached form a lower cycloalkyl group; R.sup.3 represents a methyl group having .alpha.- or .beta.-configuration; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and A.dbd. represents a cyclohexylidene moiety characteristic of the A-ring of a 1.alpha.-hydroxylated vitamin D or analogue thereof. 2. A compound as claimed in claim 1 wherein R represents a hydrogen atom, a lower alkyl or a lower alkanoyl group. 3. A compound as claimed in claim 1 in which R.sup.1 and R.sup.2 are each selected from methyl, ethyl, propyl and butyl groups. 4. A compound as claimed in claim 1 wherein Y is a straight chain group containing 3-6 carbon atoms. 5. A compound as claimed in claim 4 wherein Y is selected from trimethylene, tetramethylene, pentamethylene, hexamethylene, buta-1,3-dienylene, propynylene, but-1-ynylene and but-2-ynylene. 6. A compound as claimed in claim 1 wherein Y carries a hydroxy, etherified hydroxy or esterified hydroxy group in a position .alpha.-, .beta.- or .gamma.- to the group --C(R.sup.1) (R.sup.2).NHR or .alpha.- to any triple bond present in the group Y. 7. A compound as claimed in claim 1 wherein A.dbd. represents one of the groups ##STR18## where R.sup.4 and R.sup.5 are each selected from hydrogen atoms and O-protecting groups. 8. A compound as claimed in claim 7 wherein R.sup.4 and R.sup.5 represent etherifying silyl groups. 9. A compound as claimed in claim 7 wherein R.sup.4 and R.sup.5 are selected from hydrogen atoms and metabolically labile etherifying or esterifying groups. 10. A compound as claimed in claim 1 wherein A.dbd. represents one of the groups ##STR19## 11. A 20,20-dimethyl, 20-methylene or 20-spirocyclopropyl analogue of a compound as claimed in claim 1. 12. A Pharmaceutical composition comprising an active compound as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients. 13. A method of treatment of a human or animal subject to promote treatment and/or prevention of rickets, osteomalacia, osteoporosis, hypoparathyroidism, hypophosphataemia, hypocalcaenia and/or associated bone disease, hypocalcaemic tetiary, renal failure, renal osteodystraphy, biliary cirrhosis, steatorrhea, secondary hypocalcaemia and/or associated bone disease, wound healing, fertility control, suppression of parathyroid hormone or management of disorders involving blood clotting or to combat neoplastic disease, infection, bone disease, autoimmune disease, host-graft reaction, transplant rejection, inflammatory disease, neoplasia, hyperplasia, myopathy, enteropathy, spondylitic heart disease, dermatological disease, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia, comprising administration to said subject of an effective amount of an active compound as claimed in claim 1. 14. A process for the preparation of a compound of general formula (I) as defined in claim 1 which comprises one or more of: A) isomerising a 5,6-trans isomer of general formula (I) to a corresponding 5,6-cis isomer, followed if necessary and/or desired by removal of any O-protecting groups; B) hydroxylating a 1-unsubstituted-5,6-trans analogue of a compound of general formula (I) to prepare a 5,6-trans isomer of general formula (I), followed if necessary and/or desired by isomerisation and/or removal of any O-protecting group; C) reacting a compound containing a precursor for the desired 17-position side chain in one or more stages and with one or more reactants serving to form the desired side chain, followed if necessary and/or desired by isomerisation and/or removal of any O-protecting groups; or D) reacting a compound of formula (I) to modify the substitution pattern about the A.dbd. group, followed if necessary and/or desired by isomerisation and/or removal of protecting groups. 15. A compound: 25-amino-1.alpha.,3.beta.-dihydroxy-9,10-secocholesta-5(Z),7,10(19)-triene; 25-amino-1.alpha.,3.beta.-dihydroxy-23,24-bisnor-9,10-secocholesta-5(Z),7,1 0(19)-triene; 25-acetamido-1.alpha.,3.beta.-dihydroxy-9,10-secocholesta-5(Z),7,10(19)-tri ene; 25-amino-1.alpha.,3.beta.-dihydroxy-20-epi-9,10-secocholesta-5(Z),7,10(19)- triene; 25-amino-1.alpha.,3.beta.-dihydroxy-24-homo-9,10-secocholesta-5(Z),7,10(19) -triene; 25-amino-1.alpha.,3.beta.-dihydroxy-9,10-secocholesta-5(Z),7,10(19)-triene; 25-amino-1.alpha.,3.beta.-dihydroxy-9,10-secocholesta-5(E),7,diene; 25-amino-1.alpha.,3.beta.-dihydroxy-9,10-secocholesta-5(Z),7,diene; 25-amino-1.alpha.,3.beta.-dihydroxy-10-spirocyclopropyl-9,10-secocholesta-5 (Z),7,10(19)-triene; 25-amino-1.alpha.,3.beta.-dihydroxy-10-spirocyclopropyl-9,10-secocholesta-5 (E),7,10(19)-triene; 25-amino-1.alpha.,3.beta.-dihydroxy-20-epi-19-nor-9,10-secocholesta-5,7-die ne; 25-amino-1.alpha.,3.beta.-dihydroxy-24,26,27-tris-homo-9,10-secocholesta-5( Z),7,10(19)-triene; 25-amino-1.alpha.,3.beta.-dihydroxy-24,26,26,26,27,27,27-heptakis-homo-9,10 -secocholesta-5(Z),7,10(19)-triene; 25-acetamido-1.alpha.,3.beta.-dihydroxy-24-homo-9,10-secocholesta-5(Z),7,10 (19)-triene; 25-amino-1.alpha.,3.beta.-dihydroxy-26,27-bis-homo-9,10-secocholesta-5(Z),7 ,10(19)-trien-23-yne; 25-amino-1.alpha.,3.beta.-dihydroxy-20-epi-24,26,27-tris-homo-9,10-secochol esta-5(Z),7,10(19)-trien-24(24a)-yne; 25-amino-1.alpha.,3.beta.-dihydroxy-24-homo-9,10-secocholesta-5(Z),7,10(19) -trien-24(24a)-yne; 25-amino-1.alpha.,3.beta.-dihydroxy-20-epi-24,26,27-tris-homo-9,10-secochol esta-5(Z),7,10(19)-triene; 25-amino-1.alpha.,3.beta.-trihydroxy-26,27-bis-homo-9,10-secocholesta-5(Z), 7,10(19)-trien-23-yne; 25-amino-1.alpha.,3.beta.,23-trihydroxy-24,26,27-tris-homo-9,10-secocholest a-5(Z),7,10(19)-trien-24(24a)-yne; 25-amino-1.alpha.,3.beta.,22-trihydroxy-9,10-secocholesta-5(Z),7,10(19)-tri en-23-yne; 25-amino-1.alpha.,3.beta.-dihydroxy-22-methoxy-9,10-secocholesta-5(Z),7,10( 19)-trien-23-yne; 25-amino-1.alpha.,3.beta.-dihydroxy-22-ethoxy-9,10-secocholesta-5(Z),7,10(1 9)-trien-23-yne; 25-amino-1.alpha.,3-dihydroxy-22-propoxy-9,10-secocholesta-5(Z),7,10(19)-tr ien-23-yne; N-ethyl-25-amino-1.alpha.,3.beta.-dihydroxy-24-homo-9,10-secocholesta-5(Z), 7,10(19)-triene; 25-benzamido-1.alpha.,3.beta.-dihydroxy-24-homo-9,10-secocholesta-5(Z),7,10 (19)-triene; or 25-amino-1.alpha.,3.beta.-dihydroxy-24,26,27-tris-homo-9,10-secocholesta-5( Z),7,10(19),22,24(24a)-pentaene.

Details for Patent 5,786,347

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2013-12-13